KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Free Cash Flow (2016 - 2025)

Acadia Pharmaceuticals has reported Free Cash Flow over the past 16 years, most recently at -$52.7 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$52.7 million for Q4 2025, down 232.08% from a year ago — trailing twelve months through Dec 2025 was $105.4 million (down 32.92% YoY), and the annual figure for FY2025 was $105.1 million, down 33.11%.
  • Free Cash Flow for Q4 2025 was -$52.7 million at Acadia Pharmaceuticals, down from $73.9 million in the prior quarter.
  • Over the last five years, Free Cash Flow for ACAD hit a ceiling of $85.4 million in Q4 2023 and a floor of -$76.3 million in Q1 2022.
  • Median Free Cash Flow over the past 5 years was -$6.9 million (2022), compared with a mean of $1.9 million.
  • Peak annual rise in Free Cash Flow hit 457.97% in 2023, while the deepest fall reached 8009.35% in 2023.
  • Acadia Pharmaceuticals' Free Cash Flow stood at -$23.1 million in 2021, then decreased by 3.17% to -$23.9 million in 2022, then skyrocketed by 457.97% to $85.4 million in 2023, then plummeted by 53.24% to $39.9 million in 2024, then tumbled by 232.08% to -$52.7 million in 2025.
  • The last three reported values for Free Cash Flow were -$52.7 million (Q4 2025), $73.9 million (Q3 2025), and $64.0 million (Q2 2025) per Business Quant data.